The Longitudinal Early‐onset Alzheimer's Disease Study (LEADS): Framework and methodology
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Patients with early‐onset Alzheimer's disease (EOAD) are commonly excluded from large‐scale observational and therapeutic studies due to their young age, atypical presentation, or absence of pathogenic mutations. The goals of the Longitudinal EOAD Study (LEADS) are to (1) define the clinical, imaging, and fluid biomarker characteristics of EOAD; (2) develop sensitive cognitive and biomarker measures for future clinical and research use; and (3) establish a trial‐ready network. LEADS will follow 400 amyloid beta (Aβ)‐positive EOAD, 200 Aβ‐negative EOnonAD that meet National Institute on Aging–Alzheimer's Association (NIA‐AA) criteria for mild cognitive impairment (MCI) or AD dementia, and 100 age‐matched controls. Participants will undergo clinical and cognitive assessments, magnetic resonance imaging (MRI), [18 F]Florbetaben and [18 F]Flortaucipir positron emission tomography (PET), lumbar puncture, and blood draw for DNA, RNA, plasma, serum and peripheral blood mononuclear cells, and post‐mortem assessment. To develop more effective AD treatments, scientists need to understand the genetic, biological, and clinical processes involved in EOAD. LEADS will develop a public resource that will enable future planning and implementation of EOAD clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
Van der Auwera, G. A., Carneiro, M. O., Hartl, C., Poplin, R., del Angel, G., Levy‐Moonshine, A., Jordan, T., Shakir, K., Roazen, D., Thibault, J., et al. (2013) · Current Protocols in Bioinformatics · doi:10.1002/0471250953.bi1110s43 · Cited by 6,687
2016 Alzheimer's disease facts and figures
Alzheimer's Association (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.03.001 · Cited by 5,069
ClinVar: improving access to variant interpretations and supporting evidence
Landrum, M. J., Lee, J. M., Benson, M., Brown, G. R., Chao, C., Chitipiralla, S., Gu, B., Hart, J., Hoffman, D., Jang, W., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1153 · Cited by 4,196
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814
Self-citationHyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092 · cited 1×
“86 These guidelines focus on regions relevant to AD, Lewy body disease, TDP-43 proteinopathies, and vascular brain injury.”
Self-citation2019 Alzheimer’s disease facts and figures.
Alzheimer's Association (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.01.010 · Cited by 2,461
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationHigh performance plasma amyloid-β biomarkers for Alzheimer's disease
Nakamura, A., Kaneko, N., Villemagne, V. L., Kato, T., Doecke, J., Doré, V., Fowler, C., Li, Q.-X., Martins, R., Rowe, C., et al. (2018) · Nature · doi:10.1038/nature25456 · Cited by 1,681
The Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348
Self-citationBeach, T. G., Monsell, S. E., Phillips, L. E., & Kukull, W. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31824b211b · Cited by 1,103 · cited 2×
“De-identified data are downloaded from LONI by the LEADSMRI Core Mayo site, which employs the ADNI QC pipeline, including (1) visual inspection for artifacts (eg, subject motion) and evaluation of image quality; (2) verification of adherence to all sequence protocols (protocol consistency check) based on DICOM header…”
Self-citationDefining imaging biomarker cut points for brain aging and Alzheimer's disease
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Gunter, J. L., Senjem, M. L., Jones, D. T., Kantarci, K., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.005 · Cited by 931
Self-citationHigh-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., Holtzman, D. M., Morris, J. C., Benzinger, T. L. S., Xiong, C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008081 · Cited by 885
Self-citationCampion, D., Dumanchin, C., Hannequin, D., Dubois, B., Belliard, S., Puel, M., Thomas-Anterion, C., Michon, A., Martin, C., Charbonnier, F., et al. (1999) · The American Journal of Human Genetics · doi:10.1086/302553 · Cited by 785
Consensus classification of posterior cortical atrophy
Crutch, S. J., Schott, J. M., Rabinovici, G. D., Murray, M., Snowden, J. S., van der Flier, W. M., Dickerson, B. C., Vandenberghe, R., Ahmed, S., Bak, T. H., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2017.01.014 · Cited by 665
Self-citationBerg, L., McKeel, D. W., Miller, J. P., Storandt, M., Rubin, E. H., Morris, J. C., Baty, J., Coats, M., Norton, J., Goate, A. M., et al. (1998) · Archives of Neurology · doi:10.1001/archneur.55.3.326 · Cited by 657
Plasma β-amyloid in Alzheimer's disease and vascular disease
Janelidze, S., Stomrud, E., Palmqvist, S., Zetterberg, H., van Westen, D., Jeromin, A., Song, L., Hanlon, D., Tan Hehir, C. A., Baker, D., et al. (2016) · Scientific Reports · doi:10.1038/srep26801 · Cited by 626
Molecular genetics of early-onset Alzheimer’s disease revisited
Cacace, R., Sleegers, K., & Van Broeckhoven, C. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.01.012 · Cited by 617
The evolution and pathology of frontotemporal dementia
Kertesz, A., McMonagle, P., Blair, M., Davidson, W., & Munoz, D. G. (2005) · Brain · doi:10.1093/brain/awh598 · Cited by 609
Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study
Sabri, O., Sabbagh, M. N., Seibyl, J., Barthel, H., Akatsu, H., Ouchi, Y., Senda, K., Murayama, S., Ishii, K., Takao, M., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2015.02.004 · Cited by 602 · cited 2×
“First, scans are visually read as “amyloid-positive" or "amyloid-negative” using validated criteria 65 by a PET Core physician who has completed the manufacturer online training program and is certified to read FBB PET for clinical purposes.”
Focal cortical presentations of Alzheimer's disease
Alladi, S., Xuereb, J., Bak, T., Nestor, P., Knibb, J., Patterson, K., & Hodges, J. R. (2007) · Brain · doi:10.1093/brain/awm213 · Cited by 581 · cited 1×
“9×4mmresolution; (7) task-free functionalMRI, T2*-weighted gradient echo–echo planar sequence with TR/TE = 600/30 ms, flip”
Frontotemporal dementia: Clinicopathological correlations
Forman, M. S., Farmer, J., Johnson, J. K., Clark, C. M., Arnold, S. E., Coslett, H. B., Chatterjee, A., Hurtig, H. I., Karlawish, J. H., Rosen, H. J., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20873 · Cited by 478
Fleisher, A. S., Pontecorvo, M. J., Devous, M. D., Lu, M., Arora, A. K., Truocchio, S. P., Aldea, P., Flitter, M., Locascio, T., Devine, M., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.0528 · Cited by 448 · cited 1×
“75 Scans will be quantitatively classified as tau-positive or tau-negative based on an SUVR threshold of 1.27 76 using a temporal “meta region-of-interest.””
InfluentialSelf-citationPalmqvist, S., Janelidze, S., Stomrud, E., Zetterberg, H., Karl, J., Zink, K., Bittner, T., Mattsson, N., Eichenlaub, U., Blennow, K., et al. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1632 · Cited by 435
La Joie, R., Perrotin, A., Barré, L., Hommet, C., Mézenge, F., Ibazizene, M., Camus, V., Abbas, A., Landeau, B., Guilloteau, D., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.2170-12.2012 · Cited by 374
Jacobs, D., Sano, M., Marder, K., Bell, K., Bylsma, F., Lafleche, G., Albert, M., Brandt, J., & Stern, Y. (1994) · Neurology · doi:10.1212/wnl.44.7.1215 · Cited by 266
Autosomal Recessive Causes Likely in Early-Onset Alzheimer Disease
Wingo, T. S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.221 · Cited by 265
Self-citationCognitive Phenotypes in Alzheimer's Disease and Genetic Risk
Snowden, J. S., Stopford, C. L., Julien, C. L., Thompson, J. C., Davidson, Y., Gibbons, L., Pritchard, A., Lendon, C. L., Richardson, A. M., Varma, A., et al. (2007) · Cortex · doi:10.1016/s0010-9452(08)70683-x · Cited by 254
Impact of early onset dementia on caregivers: a review
van Vliet, D., de Vugt, M. E., Bakker, C., Koopmans, R. T. C. M., & Verhey, F. R. J. (2010) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2439 · Cited by 252
Koss, E., Edland, S., Fillenbaum, G., Mohs, R., Clark, C., Galasko, D., & Morris, J. C. (1996) · Neurology · doi:10.1212/wnl.46.1.136 · Cited by 150
Early-onset Alzheimer’s disease is associated with greater pathologic burden.
Marshall, G. A., Fairbanks, L. A., Tekin, S., Vinters, H. V., & Cummings, J. L. (2007) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988706297086 · Cited by 143
Early onset dementia: clinical and social aspects
Werner, P., Stein-Shvachman, I., & Korczyn, A. D. (2009) · International Psychogeriatrics · doi:10.1017/s1041610209009223 · Cited by 122 · cited 6×
“genetic, and biomarker data in this under-studied AD population; (2) explore the unique features of EOAD yielding novel insights into the mechanisms, heterogeneity, and heritability of AD; (3) develop clinical trial outcome measures sensitive to detect baseline deficits and track longitudinal changes in EOAD; and (4)…”
InfluentialChételat, G., Ossenkoppele, R., Villemagne, V. L., Perrotin, A., Landeau, B., Mézenge, F., Jagust, W. J., Dore, V., Miller, B. L., Egret, S., et al. (2016) · Brain · doi:10.1093/brain/aww159 · Cited by 80
Self-citationAge at onset and visuocognitive disturbances in Alzheimer disease.
Fujimori, M., Imamura, T., Yamashita, H., Hirono, N., Ikejiri, Y., Shimomura, T., & Mori, E. (1998) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199809000-00007 · Cited by 72
Longitudinal structural and metabolic changes in frontotemporal dementia
Bejanin, A., Tammewar, G., Marx, G., Cobigo, Y., Iaccarino, L., Kornak, J., Staffaroni, A. M., Dickerson, B. C., Boeve, B. F., Knopman, D. S., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000009760 · Cited by 70
Self-citation
Cited by
New insights into atypical Alzheimer's disease in the era of biomarkers
Graff-Radford, J., Yong, K. X. X., Apostolova, L. G., Bouwman, F. H., Carrillo, M., Dickerson, B. C., Rabinovici, G. D., Schott, J. M., Jones, D. T., & Murray, M. E. (2021) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30440-3 · Cited by 706
Self-citationDissecting the clinical heterogeneity of early-onset Alzheimer’s disease
Sirkis, D. W., Bonham, L. W., Johnson, T. P., La Joie, R., & Yokoyama, J. S. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01531-9 · Cited by 151
Onciul, R., Tataru, C.-I., Dumitru, A. V., Crivoi, C., Serban, M., Covache-Busuioc, R.-A., Radoi, M. P., & Toader, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14020550 · Cited by 113
“By detecting these subtle changes years before symptoms arise, AI will enable preventive interventions that preserve cognitive health [289].”
Appleton, J., Finn, Q., Zanotti-Fregonara, P., Yu, M., Faridar, A., Nakawah, M. O., Zarate, C., Carrillo, M. C., Dickerson, B. C., Rabinovici, G. D., et al. (2025) · Brain · doi:10.1093/brain/awae234 · Cited by 58
Self-citationAtypical Alzheimer Disease Variants
Polsinelli, A. J., & Apostolova, L. G. (2022) · Continuum · doi:10.1212/con.0000000000001082 · Cited by 39
Self-citation
Metadata
- Authors
- Apostolova, L. G., Aisen, P., Eloyan, A., Fagan, A., Fargo, K. N., Foroud, T., Gatsonis, C., Grinberg, L. T., Jack, C. R., Kramer, J., Koeppe, R., Kukull, W. A., Murray, M. E., Nudelman, K., Rumbaugh, M., Toga, A., Vemuri, P., Trullinger, A., Iaccarino, L., Day, G. S., Graff‐Radford, N. R., Honig, L. S., Jones, D. T., Masdeu, J., Mendez, M., Musiek, E., Onyike, C. U., Rogalski, E., Salloway, S., Wolk, D. A., Wingo, T. S., Carrillo, M. C., Dickerson, B. C., Rabinovici, G. D., & the LEADS Consortium
- Venue
- Alzheimer's & Dementia
- Publisher
- Wiley
- Published
- 2021-05-21
- Volume
- 17
- Issue
- 12
- Pages
- 2043-2055
- ISSN
- 1552-5260 (ISSN-L)
- 1552-5279
- OpenAlex
- W3163868982
- Cited by
- 92
- References
- 35
- FWCI
- 7.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.